New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
ChatGPT shows limited ability to recommend guidelines-based cancer treatments

ChatGPT shows limited ability to recommend guidelines-based cancer treatments

byBrigham and Women's HospitalCredit: Pixabay/CC0 Public DomainFor many patients, the internet serves as a powerful tool for self-education on medical topics. With ChatGPT now at patients&#3
World medicine December 05,2023
ChatGPT shows limited ability to recommend guidelines-based cancer treatments

ChatGPT shows limited ability to recommend guidelines-based cancer treatments

byBrigham and Women's HospitalCredit: Pixabay/CC0 Public DomainFor many patients, the internet serves as a powerful tool for self-education on medical topics. With ChatGPT now at patients&#3
World medicine December 05,2023
CDK9 inhibitors: A promising combination partner in treating hematological malignancies

CDK9 inhibitors: A promising combination partner in treating hematological malignancies

by Impact Journals LLCPET scan at screening (A), 5 months (B) and 8 months on treatment (C). Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28473A new research perspective titled "
World medicine December 05,2023
CDK9 inhibitors: A promising combination partner in treating hematological malignancies

CDK9 inhibitors: A promising combination partner in treating hematological malignancies

by Impact Journals LLCPET scan at screening (A), 5 months (B) and 8 months on treatment (C). Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28473A new research perspective titled "
World medicine December 05,2023
CAR-T immune therapy attacks ovarian cancer in mice with a single dose

CAR-T immune therapy attacks ovarian cancer in mice with a single dose

by Liz Ahlberg Touchstone,University of Illinois at Urbana-ChampaignScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit:
World medicine December 05,2023
CAR-T immune therapy attacks ovarian cancer in mice with a single dose

CAR-T immune therapy attacks ovarian cancer in mice with a single dose

by Liz Ahlberg Touchstone,University of Illinois at Urbana-ChampaignScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit:
World medicine December 05,2023
CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

byBaylor College of MedicineGD2-CAR.15 NKTs expand in peripheral blood, traffic to metastatic tumor sites and induce complete remission. Credit:Nature Medicine(2023). DOI: 10.1038/s4
World medicine December 05,2023
CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

CAR-NKT cell therapy shows promising results against neuroblastoma in phase 1 clinical trial

byBaylor College of MedicineGD2-CAR.15 NKTs expand in peripheral blood, traffic to metastatic tumor sites and induce complete remission. Credit:Nature Medicine(2023). DOI: 10.1038/s4
World medicine December 05,2023
What is the best lymphoma treatment after CAR T therapy fails?

What is the best lymphoma treatment after CAR T therapy fails?

by Greg Glasgow,CU Anschutz Medical CampusCredit: Pixabay/CC0 Public DomainFor 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma
World medicine December 05,2023
What is the best lymphoma treatment after CAR T therapy fails?

What is the best lymphoma treatment after CAR T therapy fails?

by Greg Glasgow,CU Anschutz Medical CampusCredit: Pixabay/CC0 Public DomainFor 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma
World medicine December 05,2023
New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

byUniversity of Maryland School of MedicineCD229 expression on CAR T cells. CD229 expression was determined on the surface of CAR T cell products at day 9 of production as well as unstimulated T
World medicine December 05,2023
New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

New innovation in CAR T cells paves way for less toxic therapy against multiple myeloma

byUniversity of Maryland School of MedicineCD229 expression on CAR T cells. CD229 expression was determined on the surface of CAR T cell products at day 9 of production as well as unstimulated T
World medicine December 05,2023
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

byScience China PressPerioperative CA242 changing patterns were defined based on preoperative and postoperative CA242 levels, and longitudinal CA242 trajectories were fitted using repeated CA242
World medicine December 05,2023
Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

byScience China PressPerioperative CA242 changing patterns were defined based on preoperative and postoperative CA242 levels, and longitudinal CA242 trajectories were fitted using repeated CA242
World medicine December 05,2023
CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

by Impact Journals LLCKaplan-Meier survival curve of duodenal adenocarcinoma patients with elevated CA 19-9 (green) and with normal CEA (blue). Credit:Oncotarget(2023). DOI: 10.18632/oncot
World medicine December 05,2023
CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

by Impact Journals LLCKaplan-Meier survival curve of duodenal adenocarcinoma patients with elevated CA 19-9 (green) and with normal CEA (blue). Credit:Oncotarget(2023). DOI: 10.18632/oncot
World medicine December 05,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com